In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1
Reference: 1. AREXVY Product Information
This video was developed by Heathed with funding from GSK.
Views of the speaker are their own and do not necessarily reflect that of GSK. GSK recommends usage in accordance with the Product Information.
PM-AU-RSA-WCNT-240007 Date of approval: March 2024.
